[Induction of bradycardia by mibefradil in antihypertensive combination therapy].
Wagner
J
J
Ritz
E
E
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced*; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D020748:Mibefradil; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil
Induktion von Bradykardie durch Mibefradil bei antihypertensiver Kombinationstherapie.